Mississauga, ONTARIO (November 10, 2022)—PointClickCare Technologies, a health care technology platform, has announced a strategic collaboration with Pfizer Inc. to provide real-world insights into the population at high risk of age-related disorders.
Older adults are at risk of developing age-related disorders such as loss of appetite, malnutrition, involuntary weight loss and cachexia, which can lead to adverse health outcomes. Because these disorders likely affect many older adults, there is a need to better understand how these disorders manifest, how they progress over time, and how they impact patient health. More comprehensive data is needed to help fill these knowledge gaps.
“Real-world evidence is at the root of an ongoing and critical transformation in health care," Simon Dagenais, senior director of the Real World Evidence Center of Excellence at Pfizer, said in a news release. "By analyzing real-world data, we can learn more about a patient population. And those insights can help guide our decisions about developing new therapies.”
Globally, the population is aging rapidly. Between 2015 and 2050, the proportion of the world’s population over age 60 will nearly double, from 12% to 22%. In the United States, the number of individuals older than age 65 is projected to peak at 95 million in 2060. Many older adults will need to spend time in a long-term care facility as they age, but older adults in long-term care facilities are often unable to participate in clinical trials. This lack of representation can limit the development of therapies aimed at addressing the unmet needs of this important population.
“Our evidence-rich database can provide insights that specifically represent older adults in long-term care facilities —a population that is often overlooked—to support research by expanding drug discovery and development, said Jeff Wessinger, Vice President and general manager of Life Sciences at PointClickCare. "We’re proud to support companies, like Pfizer who are doing their part to accelerate research for this demographic and make trials more inclusive, to ultimately improve care outcomes.”
With coverage approaching 70% of the long-term and post-acute care (LTPAC) market, PointClickCare is uniquely positioned to provide life sciences companies, like Pfizer, with outcomes-based evidence through extensive longitudinal patient records. The continued collaboration between LTPAC and Life Sciences companies is powering this innovation.
